FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new compounds of formula (I): , where: R1 is selected from -ORa, -C(O)NRaRb, -NHS(O)2Rc, -C(O)ORa; A means C1-4alkylenyl; R2 means C3-12cycloalkyl or C6-10aryl which is optionally substituted by one -ORa, one or two halogen atoms, one or two C1-3alkyls substituted by two or three halogen atoms; or one, two, three or four C1-3alkyls; G means C1-4alkylenyl; R3 is selected from hydrogen, -C(O)R4, -C(O)NHR5, -S(O)2Rc and -S(O)2NRaRb; R4 means C3-6cycloalkyl or C1-6alkyl, C3-6cycloalkyl is optionally substituted by one -ORa, and C1-6alkyl is optionally substituted by one or two substitutes selected from -ORa, -C(O)ORa, -S(O)2R6, -C(O)NRaRb, -NRaRb, -CN, C3-6cycloalkyl and phenyl; or by one -D-(CH2)j-R7 where D means , j is equal to 1, n is equal to 1 or 2; R6 means C1-3alkyl optionally substituted by R7; R7 means -C(O)ORa; R5 means C1-6alkyl, benzo[1.3]dioxole or -(CH2)q-phenyl; where phenyl is optionally substituted by one or two substitutes selected from halogen, -ORa, C1-3alkiyl and C1-3alkoxy where C1-3alkyl and C1-3alkoxy optionally substituted by 2 or 3 halogen atoms, and q is equal to 0, 1; Ra and Rb independently mean hydrogen or C1-4alkyl; and Rc means C1-3alkyl; provided when R2 means phenyl substituted in position 4, R3 is not -C(O)R4 where R4 means C1-4alkyl substituted by C(O)ORa; to their pharmaceutically acceptable salts. Also, the invention refers to a pharmaceutical composition, to a method of preparing the compound of formula (I), to compounds of formula (II), (III), to application of the compounds on any claim 1-14, to a method of analysing a biological system or a sample containing a mu-opioid receptor, and also to a method of treating a mammal suffering a disease caused by mu-opioid receptor activity.
EFFECT: production of the new biologically active compounds exhibiting mu-opioid receptor antagonist activity.
26 cl, 204 ex
Title | Year | Author | Number |
---|---|---|---|
CRYSTALLINE FORMS OF 8-AZABICYCLO[3,2,1]OCTANE COMPOUND | 2008 |
|
RU2458061C2 |
METHOD OF PRODUCING INTERMEDIATE PRODUCT FOR SYNTHESIS OF mu OPIOID RECEPTOR ANTAGONISTS | 2008 |
|
RU2469035C2 |
INDAZOLE-CARBOXAMIDE COMPOUNDS | 2005 |
|
RU2404179C2 |
AZABICYCLIC ALKANE DERIVATIVES SUBSTITUTED WITH CONDENSED BICYCLOHETEROCYCLE | 2007 |
|
RU2437884C2 |
QUINOLINONE-CARBOXAMIDE COMPOUNDS AS AGONISTS OF 5-HT RECEPTORS | 2005 |
|
RU2394033C2 |
HISTONE DEACETYLASE INHIBITORS | 2016 |
|
RU2720678C2 |
APOPTOSIS INDUCING AGENTS FOR TREATING CANCER, IMMUNE AND AUTOIMMUNE DISEASES | 2011 |
|
RU2568611C2 |
DERIVATIVES OF BENZIMIDAZOLIDINONE AS AGENTS FOR MUSCARINIC RECEPTORS | 2002 |
|
RU2288919C2 |
DERIVATIVE OF AMINOBENZOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALT | 1993 |
|
RU2067979C1 |
AZABICYCLOOCTANE DERIVATIVE, PHARMACEUTICAL PREPARATIONS, METHOD FOR PROPHYLAXIS OR TREATMENT, METHODS FOR PREPARING COMPOUNDS, COMPOUNDS | 2000 |
|
RU2262505C2 |
Authors
Dates
2011-07-10—Published
2007-02-28—Filed